Stockreport

Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre’s Novel Mechanism of Action in Diabetes

Acasti Pharma, Inc. - Class A  (ACST) 
Last acasti pharma, inc. - class a earnings: 2/14 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: acastipharma.com/investors
PDF Data from a new preclinical mouse study suggests a unique mechanism of CaPre compared to metformin and icosapent ethyl (VASCEPA®) in a diet-induced obesity animal model  [Read more]